Congress orders audit of drug-pricing incentives buried in supply chain
S. 3751 — Prescription Drug Supply Chain Pricing Transparency Act · Filed by Michael Bennet (D-CO) · 1 cosponsor · Introduced Jan 29, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Government Accountability Office (GAO) to study how prescription drug prices are used to calculate payments and fees between companies in the drug supply chain—pharmacies, insurers, drug makers, and middlemen—and to report back to Congress within two years with findings and recommendations. The study will examine whether these price-based payment structures create conflicts of interest that might incentivize the promotion of more expensive drugs.
Why we flagged it
The bill is a straightforward directive to the GAO to conduct a study and report on a specific structural issue in the prescription drug supply chain. It is not a regulatory change, appropriation, or carve-out—purely an information-gathering and reporting requirement.
What the text implies
- Study findings may reveal that pharmacy benefit managers (PBMs) and other intermediaries have financial incentives to favor higher-priced drugs, potentially supporting future legislation to restructure their compensation models or increase regulatory oversight.
- The two-year timeline positions the report for the 118th Congress (2027–2028), potentially influencing drug-pricing legislation in a future session.
- Study scope includes Medicaid (Title XIX) alongside Medicare Part D, broadening the investigation to cover both federal programs and potentially state-level implications.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Citizens pay for prescription drugs directly and through insurance premiums. A transparent study of how intermediaries are paid based on drug prices can expose whether the supply chain's financial incentives push toward costlier medications, enabling Congress to address structural cost drivers. The bill creates no new restrictions on citizens and imposes no direct costs; it is purely investigative.
Named in the bill
Government Accountability Office (GAO), Comptroller General of the United States, Pharmacy Benefit Managers (PBMs), Part D Plan Sponsors, Drug Wholesalers, Pharmacies, Pharmaceutical Manufacturers, Pharmacy Services Administrative Organizations (PSAOs), Rebate Aggregators, Medicare Part D, Medicaid (Title XIX), Social Security Act Section 1860D–42
Where it stands
1 cosponsor: 1 Republicans.
- Jan 29, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Jan 29, 2026 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $3,010,000 in lobbying spend. A filing names 77 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Michael Bennet, the sponsor, reported $21,000 in PAC receipts in the 2026 cycle.
- America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (3,126 characters) on May 21, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress orders audit of drug-pricing incentives buried in supply chain” QuorumCivic. https://share.quorumcivic.app/bill/119/s3751 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.